KR20110021946A - 니코틴 수용체 부분 효능제와 아세틸콜린에스테라제 억제제의 조합물, 이를 함유하는 제약 조성물, 및 인지 장애를 치료하는 데에 있어서의 그의 용도 - Google Patents
니코틴 수용체 부분 효능제와 아세틸콜린에스테라제 억제제의 조합물, 이를 함유하는 제약 조성물, 및 인지 장애를 치료하는 데에 있어서의 그의 용도 Download PDFInfo
- Publication number
- KR20110021946A KR20110021946A KR1020107029081A KR20107029081A KR20110021946A KR 20110021946 A KR20110021946 A KR 20110021946A KR 1020107029081 A KR1020107029081 A KR 1020107029081A KR 20107029081 A KR20107029081 A KR 20107029081A KR 20110021946 A KR20110021946 A KR 20110021946A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- combination
- alpha
- partial agonist
- receptor partial
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0802996A FR2931677B1 (fr) | 2008-06-02 | 2008-06-02 | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
FR0802996 | 2008-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20110021946A true KR20110021946A (ko) | 2011-03-04 |
Family
ID=40229706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020107029081A KR20110021946A (ko) | 2008-06-02 | 2009-06-02 | 니코틴 수용체 부분 효능제와 아세틸콜린에스테라제 억제제의 조합물, 이를 함유하는 제약 조성물, 및 인지 장애를 치료하는 데에 있어서의 그의 용도 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20110136791A1 (zh) |
EP (1) | EP2293790A2 (zh) |
JP (1) | JP2011522017A (zh) |
KR (1) | KR20110021946A (zh) |
CN (1) | CN102046164B (zh) |
AU (1) | AU2009264016B2 (zh) |
BR (1) | BRPI0913236A2 (zh) |
CA (1) | CA2726291A1 (zh) |
FR (1) | FR2931677B1 (zh) |
HK (1) | HK1155943A1 (zh) |
IL (1) | IL209601A0 (zh) |
MX (1) | MX2010013241A (zh) |
RU (1) | RU2493851C2 (zh) |
SG (1) | SG191623A1 (zh) |
WO (1) | WO2009156680A2 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0424564D0 (en) * | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
US8314119B2 (en) * | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
WO2012040404A1 (en) | 2010-09-23 | 2012-03-29 | Abbott Laboratories | Monohydrate of an azaadamantane derivative |
US9829326B2 (en) | 2012-04-14 | 2017-11-28 | Audi Ag | Method, system and vehicle for conducting group travel |
CN103333163A (zh) * | 2013-07-09 | 2013-10-02 | 广州中医药大学 | 一种苯并呋喃类衍生物及其制备方法和应用 |
EP3200828B1 (en) * | 2014-10-03 | 2020-08-12 | Lachesis Biosciences Limited | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
RU2624978C2 (ru) * | 2015-07-27 | 2017-07-11 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Способ лечения умеренного когнитивного снижения |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2237163T3 (es) * | 1998-10-01 | 2005-07-16 | Novartis Ag | Nuevas formulaciones orales de revastigmina de liberacion controlada. |
FR2791678B1 (fr) * | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
US20010036949A1 (en) * | 2000-05-09 | 2001-11-01 | Coe Jotham Wadsworth | Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
EP1231212B1 (en) * | 2001-02-06 | 2006-12-20 | Pfizer Products Inc. | Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders |
KR100861466B1 (ko) * | 2001-04-24 | 2008-10-02 | 메르크 파텐트 게엠베하 | 항혈관형성제 및 TNFα를 이용한 병용 요법 |
GEP20094759B (en) * | 2002-10-24 | 2009-08-25 | Merz Pharma Gmbh & Co Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
JP2006510662A (ja) * | 2002-12-11 | 2006-03-30 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | α7ニコチン性アセチルコリン受容体アゴニストとその他の化合物との組合せによる疾患の治療 |
DK1641454T3 (da) * | 2003-06-27 | 2009-02-09 | Pfizer Prod Inc | Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere |
US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
JP2007519733A (ja) * | 2004-01-26 | 2007-07-19 | コーテックス ファーマシューティカルズ インコーポレーティッド | アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法 |
TW200533371A (en) * | 2004-04-15 | 2005-10-16 | Dainippon Pharmaceutical Co | Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative |
WO2005111038A2 (en) * | 2004-05-07 | 2005-11-24 | Memory Pharmaceuticals Corporation | 1h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof |
US20060194723A1 (en) * | 2005-02-28 | 2006-08-31 | Rabinoff Michael D | Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement |
JP2009526776A (ja) * | 2006-02-14 | 2009-07-23 | ノイロサーチ アクティーゼルスカブ | 新規なジアザビシクロアルカン誘導体及びその医療上の使用 |
US20100234349A1 (en) * | 2006-09-04 | 2010-09-16 | Olsen Gunnar M | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
JP2010523587A (ja) * | 2007-04-02 | 2010-07-15 | パーキンソンズ インスティテュート | 治療処置の副作用の低減のための方法および組成物 |
ES2442932T3 (es) * | 2008-03-19 | 2014-02-14 | Janssen Pharmaceutica N.V. | 1,2,4-Triazoles trisustituidos como moduladores de receptores nicotínicos de acetilcolina |
EA018187B1 (ru) * | 2008-05-09 | 2013-06-28 | Янссен Фармацевтика Нв | Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина |
-
2008
- 2008-06-02 FR FR0802996A patent/FR2931677B1/fr not_active Expired - Fee Related
-
2009
- 2009-06-02 KR KR1020107029081A patent/KR20110021946A/ko not_active Application Discontinuation
- 2009-06-02 JP JP2011512185A patent/JP2011522017A/ja not_active Ceased
- 2009-06-02 WO PCT/FR2009/051041 patent/WO2009156680A2/fr active Application Filing
- 2009-06-02 BR BRPI0913236A patent/BRPI0913236A2/pt not_active IP Right Cessation
- 2009-06-02 SG SG2013041421A patent/SG191623A1/en unknown
- 2009-06-02 CA CA2726291A patent/CA2726291A1/fr not_active Abandoned
- 2009-06-02 CN CN2009801204747A patent/CN102046164B/zh not_active Expired - Fee Related
- 2009-06-02 MX MX2010013241A patent/MX2010013241A/es active IP Right Grant
- 2009-06-02 EP EP09769521A patent/EP2293790A2/fr not_active Withdrawn
- 2009-06-02 RU RU2010154417/15A patent/RU2493851C2/ru not_active IP Right Cessation
- 2009-06-02 AU AU2009264016A patent/AU2009264016B2/en not_active Ceased
-
2010
- 2010-11-28 IL IL209601A patent/IL209601A0/en unknown
- 2010-12-01 US US12/958,025 patent/US20110136791A1/en not_active Abandoned
-
2011
- 2011-09-23 HK HK11110041.5A patent/HK1155943A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2493851C2 (ru) | 2013-09-27 |
WO2009156680A3 (fr) | 2010-04-22 |
AU2009264016A1 (en) | 2009-12-30 |
FR2931677A1 (fr) | 2009-12-04 |
FR2931677B1 (fr) | 2010-08-20 |
AU2009264016B2 (en) | 2014-09-11 |
HK1155943A1 (en) | 2012-06-01 |
IL209601A0 (en) | 2011-02-28 |
WO2009156680A2 (fr) | 2009-12-30 |
CN102046164B (zh) | 2013-02-20 |
JP2011522017A (ja) | 2011-07-28 |
SG191623A1 (en) | 2013-07-31 |
BRPI0913236A2 (pt) | 2016-01-19 |
EP2293790A2 (fr) | 2011-03-16 |
MX2010013241A (es) | 2011-01-21 |
CA2726291A1 (fr) | 2009-12-30 |
RU2010154417A (ru) | 2012-07-20 |
US20110136791A1 (en) | 2011-06-09 |
CN102046164A (zh) | 2011-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6106361B2 (ja) | 睡眠障害および他の障害のための方法および組成物 | |
KR20110021946A (ko) | 니코틴 수용체 부분 효능제와 아세틸콜린에스테라제 억제제의 조합물, 이를 함유하는 제약 조성물, 및 인지 장애를 치료하는 데에 있어서의 그의 용도 | |
US6608085B1 (en) | 4-quinolinemethanol derivatives as purine receptor antagonists (II) | |
CN113271936A (zh) | 治疗神经和精神疾病的方法 | |
JP5666910B2 (ja) | 認知機能障害を治療するためのキット、組成物、製品もしくは医薬 | |
JP2015007096A (ja) | 運動障害の予防および/または治療剤 | |
EP1937263A2 (en) | Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease | |
JP2003530345A (ja) | 急性、慢性疼痛及び/またはニューロパシー性疼痛及び片頭痛の治療のための医薬組成物 | |
JP2004527500A (ja) | 認識障害の治療のためのニコチン受容体部分アゴニスト、エストロゲン、選択的エストロゲン調節剤又はビタミンeとgabaa逆アゴニストの併用 | |
MXPA05010171A (es) | Agonistas de receptor muscarinico m1 para manejo del dolor. | |
KR20200020726A (ko) | 외상 후 스트레스 장애의 치료를 위한 제제 | |
KR20230003503A (ko) | 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민 | |
RU2011146032A (ru) | Соединения-агонисты рецептора 5-ht4 для лечения расстройств познавательной способности | |
ES2250345T3 (es) | Derivados sustituidos de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico. | |
KR20200133259A (ko) | Kv7 채널 활성화제 조성물 및 이의 사용 방법 | |
JP2575569B2 (ja) | 薬物従属症及び禁断症状の治療に関するグリシン/nmdaレセプターリガンドの用法 | |
CN105209445B (zh) | 治疗运动障碍和相关病症的方法 | |
JPH08500326A (ja) | 免疫抑制剤としてのスピペロンまたはスピペロン誘導体の使用 | |
RU2258506C2 (ru) | Лекарственные средства для предупреждения и лечения нейродегенеративных заболеваний | |
US7754754B2 (en) | Pharmaceutical formulations containing substituted 2 heteroarylaminoacetic acid compounds | |
WO2022197885A1 (en) | Compositions and methods for treating neurologic diseases | |
US7432296B2 (en) | Pharmaceutical formulations containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds | |
JP2010530900A (ja) | 中枢神経系活性を有する置換ピロリジン化合物 | |
CA3176643A1 (en) | Use of dopamine d3 partial agonists for treating central nervous system disorders | |
CA2520680A1 (en) | Antitussives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |